drugset / Trial / NCT01646567
SHP-141C in Plaque Type Psoriasis
NaSingle-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the safety, tolerability and clinical activity of the SHP-141C topical cream formulations in patients with plaque type psoriasis.
Timeline
- Start
- 2012-09
- Primary completion
- 2012-11
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcipotriol | Small molecule | 0.005 % | Topical |
| Subject | SHP-141C | Unknown | 0.5 % | Topical |
| Subject | SHP-141C | Unknown | 1 % | Topical |
| Subject | SHP-141C | Unknown | 2 % | Topical |
| Subject | SHP-141C | Unknown | 100 mg | Topical |
| Subject | betamethasone valerate | Small molecule | 0.02 % | Topical |